CG Oncology (CGON) is trading higher today as the market refocuses on its 2026 catalyst calendar for cretostimogene grenadenorepvec in non-muscle invasive bladder cancer, with a key Phase 3 PIVOT-006 topline readout expected in the first half of 2026 after the company pulled the timing forward. The combination of a near-dated, binary biotech catalyst and a meaningful short base is supporting momentum buying on a green tape day for the name. (investing.com)

The biggest near-term driver for sentiment is the accelerated PIVOT-006 readout window (now first half of 2026), which tightens the timeline for potentially practice-changing data in intermediate-risk NMIBC. Separately, the company has guided to continued progress toward a BLA for its initial high-risk NMIBC indication, keeping regulatory expectations in play for later in 2026 and raising the stakes around any incremental positive signal flow. (investing.com)

Positioning looks primed to magnify day-to-day moves: reported short interest stood at about 10.54 million shares, roughly 13.48% of the public float as of March 31, 2026. With that level of short exposure, modest incremental demand—whether from catalyst trading, quant/technical flows, or options-related hedging—can translate into outsized price swings. (marketbeat.com)

Key swing factors for CGON over the coming weeks include any additional clarity on the timing and content of the PIVOT-006 topline dataset, interim updates around its broader bladder-cancer development program, and further Street research actions following recent price-target activity. The next major step-change event for valuation remains delivery of Phase 3 topline data in the first half of 2026, with investors also tracking the path toward a potential late-2026 regulatory decision timeline for the initial indication. (investing.com)